/
BDRX
$2.85-$0.07 (-2.40%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$2.2M
1M shares
52-week range
$2.45 – $66.50
1% from low
Exchange
NASDAQ
ADRC
Borrow rate
256.57%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-47027.15
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.9M | $674.0K | $343.0K | $578.0K | $699.0K | $381.0K | $0 | $0 |
| Cost of revenue | $9.4M | $7.8M | $6.1M | $4.7M | $5.1M | $4.1M | $5.4M | $184.9K |
| Gross profit | −$7.4M | −$7.2M | −$5.7M | −$4.1M | −$4.4M | −$3.7M | −$5.4M | −$184.9K |
| Gross margin | -382.9% | -1063.6% | -1669.1% | -705.2% | -631.2% | -967.5% | — | — |
| R&D | $9.4M | $7.8M | $16.1M | $4.7M | $5.1M | $4.1M | $5.4M | $3.7M |
| Operating income | −$11.8M | −$11.3M | −$23.0M | −$7.0M | −$8.9M | −$8.0M | −$9.2M | −$8.3M |
| EBITDA | −$10.7M | −$9.5M | −$22.2M | −$5.7M | −$8.3M | −$7.2M | −$9.1M | −$8.1M |
| Net income | −$10.4M | −$10.1M | −$22.2M | −$5.5M | −$7.7M | −$7.1M | −$5.7M | −$6.2M |
| Net margin | -535.0% | -1496.3% | -6469.1% | -944.6% | -1095.3% | -1858.0% | — | — |
| EPS (diluted) | -292803790.00 | -35095575.00 | -33209775.00 | -4661590.00 | -4770680.00 | -69640.00 | -3705.65 | -400.00 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $5687 | $-0.00 | $-0.00–$-0.00 | 1 |
| 2027 | $2843 | $-0.00 | $-0.00–$-0.00 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$513.26
Price
$2.85
Implied upside
+17909%
Peer comparison
Biodexa Pharmaceuticals plc American Depositary Shs
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
www.biodexapharma.com- Employees
- 11
- IPO / List date
- Dec 7, 2015
Held by traders on TradeandTell
No one on the platform currently holds BDRX.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in BDRX as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-04-06 | 1-for-5reverse |
| 2025-07-31 | 1-for-10reverse |
| 2024-10-04 | 1-for-25reverse |
| 2023-07-05 | 1-for-80reverse |
| 2023-03-27 | 1-for-4reverse |
Recent trades on TradeandTell
No one on the platform has traded BDRX yet.
